<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 5, 2019 (HealthDay News) — The burden of new-onset atrial fibrillation is considerable following transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (AVR), and the odds of in-hospital mortality are increased with new-onset atrial fibrillation, according to a study published online June 3 in JAMA Internal Medicine<\/i>.<\/p>\n
In a population-based observation study, Rajat Kalra, M.B.Ch.B., from the University of Minnesota in Minneapolis, and colleagues examined the incidence of new-onset atrial fibrillation and the incidence of in-hospital mortality associated with this atrial fibrillation after TAVI and AVR. Data were included for 48,715 TAVI hospitalizations and 122,765 AVR hospitalizations from the National Inpatient Sample.<\/p>\n
The researchers found that new-onset atrial fibrillation occurred in 50.4 and 50.1 percent of TAVI and AVR hospitalizations, respectively. Compared with hospitalizations without new-onset atrial fibrillation, the odds of in-hospital mortality were increased in TAVI and AVR hospitalizations with new-onset atrial fibrillation in the multivariable-adjusted model (odds ratios, 1.57 and 1.36, respectively). These results were confirmed in the New York state inpatient database, with incidence rates of new-onset atrial fibrillation of 14.1 and 30.6 percent after TAVI and AVR, respectively.<\/p>\n
“The use of TAVI and aortic valve replacement will only continue to increase as the American population ages,” Kalra said in a statement. “However, we are now acknowledging that there can be many unintended effects from TAVI and surgical aortic valve replacement.”<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n